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ABSTRACT
Objective: D-amino acid oxidase inhibitors (DAAOIs) are of particular focus for cognition study. Atypical antipsychotics are known DAAO inhibitors. 
The present examination was done to check out the binding affinity of atypical antipsychotics by docking toward the DAAO protein; in conclusion, the 
picked antipsychotic drug was checked for their cognition enhancing activity with scopolamine-induced amnesia.
Methods: The crystal structure of DAAO was obtained from Protein Data Bank, the energy minimization was performed with CHARMM program, then 
active site prediction was made out using Ramachandran plot, and finally, docking examination was finished using Autodock 4.2 tool. For in vivo study, 
the mice were divided into three groups. Group I - vehicle (Saline) treated, Group II – saline +scopolamine (1 mg/kg, intraperitoneal [i.p]) treated, and 
Group III - clozapine (20 mg/kg, i.p) + scopolamine (1 mg/kg, i.p).
Results: The Autodock examination shows significant binding affinity of - 5.22 for brexpiprazole and least or positive binding affinity of +1 for 
iloperidone. Clozapine with binding energy of - 2.87 was decided for completing the in vivo cognition study. The in vivo shows up that clozapine 
(20 mg/kg, i.p) exhibits a change in the impairment of spatial memory.
Conclusion: The results recommend that the clozapine produces cognitive enhancement through both DAAOI and antipsychotic action. Clozapine has 
cognitive improvement potential, favoring its usage in reducing toxic impacts of scopolamine
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INTRODUCTION
D-amino acid oxidase (DAAO) is a flavoenzyme that degrades the 
D-amino acids through the system of oxidative deamination. DAAO 
control of keeping up D-amino acid levels has been connected with a 
couple of physiological techniques running from hormone secretion 
to synaptic transmission and cognition [1]. Preclinical figures suggest 
that second-generation antipsychotics could diminish cognitive 
impairment [2]. Second-generation antipsychotics have regularly 
outflanked their original partners in switching or weakening 
phencyclidine- or methamphetamine-instigated shortfalls in inversion 
learning, restrictive learning, consideration, spatial memory, spatial 
learning, and long-haul potentiating effect in rodents and nonhuman 
primates [3].
In this work, we predict the three-dimensional (3D) structure and the 
protein-ligand and protein-protein docking of DAAO using various 
Bioinformatics methods. The essential purpose of our investigation was 
to expect the 3D structure and docking. The objective of the present 
examination was to clear up the participations of DAAO proteins with 
ligands and distinctive proteins and to perceive the relationship of 
DAAO to insight. Protein-protein docking and association reproduction 
reveal hydrogen and ionic bonds.
Scopolamine, a non-selective muscarinic receptor antagonist, causes 
debilitation in learning and memory by decreasing cholinergic action. 
On intraperitoneal (i.p.) administration of scopolamine, the cholinergic 
neurotransmission was blocked, provoking cholinergic brokenness and 
obstructed cognitive impairment in mice [4]. Starting late, it has been 
represented that memory impairment induced by scopolamine in mice 
is connected with changed cerebral amino acid levels by the protein 
DAAO. Along these lines, mice with scopolamine-induced memory 
deficiencies were used as an animal model for the screening of cognitive 
enhancement agents.
Here, we investigate whether the neuroprotective effect of clozapine 
reduced learning and memory impairment induced by a muscarinic 
antagonist scopolamine in mice. We assessed the effect of clozapine on 




Retrieval of crystal structure and target preparation
The high-resolution crystal structure of human DAAO was retrieved 
from the Protein Data Bank. FASTA sequence of the retrieved structure 
revealed the presence of glycine at position. The target was pre-
processed by standard methods before binding analysis [5].
Energy minimization [6]
CHARMM is a general and flexible program for macromolecular energy 
minimization and dynamic calculations that utilize both classical and 
quantum mechanical energy functions for molecular systems. Energy 
minimization of target enzyme was carried out under CHARMM27 force 
field. Gradient was set to 0.05.
Structural assessment of proteins [7]
3D structure and conformational stability of the protein were analyzed 
by means of Ramachandran plot.
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2018.v11i7.26800
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Active site prediction [8]
The ligand-binding domain of the human DAAO was predicted using the 
Site Finder module of the molecular operating environment.
Molecular docking analysis [9]
To understand the binding conformation and affinity, antipsychotics were 
individually docked to the active site of human DAAO. Autodock 4.2 tool was 
used for molecular docking analysis. Both the receptor and ligands were 
prepared by the addition of hydrogen and Gasteiger charges. A grid defining 
the active site was constructed before running the docking simulation. 
Genetic algorithm was adopted for conformer search while docking.
In vivo methods
Animals
Male Swiss Albino mice (25–30 g: 24 mice) were obtained from the Animal 
house, TANUVAS, Chennai, and housed into four groups of six mice each. The 
mice were housed in cages at a distorted temperature of 25°C±2°C with a 
12 h light/dark cycle. The animals had free access to standard pellet eating 
regimen and drinking water. Behavioral studies were performed in a silent 
room between 9.00 am and 11.00 am to stay away from circadian variation. 
The investigation was endorsed by the Institutional Animal Ethical 
Committee, and work was completed according to the CPCSEA Guidelines, 
New Delhi. XIX/VELS/PCOL/05/2000/CPCSEA/IAEC/03.10.2016
Drugs and chemicals
Scopolamine (Sigma-Aldrich), Clomach (La Pharmaceuticals, 
Ahmedabad), and sodium chloride (Sigma-Aldrich) were utilized. Every 






To observe the impact of clozapine, antipsychotic drug on scopolamine 
induced amnesia in eighteen mice (6 in every group were divided into 
three groups), the control group received vehicle (saline, 0.9% NaCl 
2) once daily for 18 days, the second group received saline for 15 days 
followed by scopolamine (1 mg/kg i.p.) for 3 days, and the third group 
received Clozapine (20mg/kg, i.p) for 15 days followed by scopolamine 
(1 mg/kg i.p.) for 3 days All drugs were ready, freshly prepared and 
given once daily within the morning and followed an equivalent 
program. The training and memory parameters were performed 
120 min once after drug administration. On the day 18, behavioral 
study for finding the escape latency and time spent on platform 
quadrant are carried out.
Learning and memory evaluation: Morris maze test [11]
Spatial learning and memory were assessed by the Morris water maze. 
The technique included two stages. The initial step was the place 
navigation test from day 1 to 4, in which the escape latency (EL) (the 
time required to escape onto the hidden platform) was utilized to assess 
learning and memory function. Mice that found the platform were 
permitted to stay on the platform for 20 s and were then come back to 
the home cage. On the off chance that mice did not achieve the platform 
inside 120 s, it was tenderly guided to the platform by the experimenter, 
where it stayed for 20 s. The last trial was viewed as the probe test. 
The second step was the spatial test on day 5 after evacuation of the 
platform and after the probe test, which was performed to test the 
capacity of mice to locate the expelled platform by memory
RESULTS
In silico
Energy minimization of DAAO was carried out. The initial and post-
minimization potential energies are listed in Table 1.
The conformation and stability of the enzyme were analyzed in terms 
of its dihedral angles phi and psi using Ramachandran plot. A typical 
Ramachandran plot consists of a favored, allowed, and disallowed 
region. The Ramachandran plot of human DAAO is shown in Fig. 1.
Table	 2	 shows	 the	 effect	 of	 clozapine	 (20	mg/Kg,	 i.p)	 on	 (a)	 escape	
latency and (b) time spent, in the Morris water maze test. Clozapine 
(20	 mg/Kg,	 i.p)	 was	 administered	 to	 the	 mice.	 The	 mice	 were	 then	
treated with scopolamine (1 mg/kg) and tested in the Morris water 
maze test. Probe trial sessions were performed for 60 s. The data 
represent mean ± standard error of mean **p<0.001 compared to 
scopolamine-treated mice
In vivo
The result of clozapine on scopolamine-induced memory deficit was 
evaluated using Morris water maze (Fig. 2). Morris water maze evaluates 
spatial, working, and reference memory. During this study, the escape 
latency time in animals administered by scopolamine was considerably 
reduced by clozapine-treated group (20.35±5.7**) compared with the 
group received vehicle only (32.21±2.69) as shown in Table 2.
Table 1: Energy minimization of human DAAO
S. No Type of variant Pre‑minimization potential energy Post‑minimization potential energy
1 HS-DAO 5150.8530 kcal/mol −744.0501	kcal/mol
*Force field: CHARMM27, Gradient: 0.05, H and LP adjusted. DAAO: D-amino acid oxidase
Table 2: Effect of clozapine on scopolamine‑induced amnesia
S. No Groups Treatment Escape latency (sec) Time spent in platform quadrant (sec)
1 Group I Saline treated (10 mL/kg, i.p.,) (Vehicle) 32.21±2.69 29.37±3.57
2 Group II Saline (10 mL/kg, i.p.,)+Scopolamine (1 mg/kg, i.p) 49.47±10.32 46.39±3.8
3 Group III Clozapine (20 mg/kg, i.p)+Scopolamine (1 mg/kg, i.p) 20.35±5.7** 22.43±2.5**
Fig. 1: Ramachandran plot of D‑amino acid oxidase
495
Asian J Pharm Clin Res, Vol 11, Issue 7, 2018, 493-496
 Nithya and Shanmugarajan 
DISCUSSION
To gain better insight for the interactions between antipsychotics and 
DAAO, molecular docking studies were carried out. The interactions 
of the ligands with the active site residues (Table 3) of the target are 
analyzed in terms of the following parameters: Binding energy, number 
of hydrogen bonds established by the ligand with residues of the active 
site,	π-π	 interactions,	conformation	oriented	by	the	 ligand	within	the	
active site, and root mean square deviation (RMSD) of the active site 
residues. The dock score of Autodock is reported in kcal/mol. Autodock 
uses the following empirical formula to calculate the free energy of 
binding:
Binding	energy	(ΔG)	=	Intermolecular	energy	+	van	der	Waals	hydrogen	
bond desolvation energy + electrostatic energy + total internal energy + 
torsional energy – unbound energy of the system.
Desolvation energy is a prime parameter that decides a molecules 
interaction with its pharmacodynamic target [5]. In the biological 
environment, all drug binding pockets of a target protein remain 
solvated, and hence, a ligand cannot as such occupy the active site unless 
it dislodges the water molecules. The similarity of docked structures 
is measured by computing the RMSD, and clusters are created based 
on the comparison of conformations and estimated RMSD values 
[12,13-16]. The docking score of selected ligands with DAO is shown 
in Table 4, and Fig. 3 shows the 3D docked confirmations of atypical 
antipsychotic agents.
Impairment of memory and learning and the foremost characteristic 
manifestation of psychological feature dysfunction are caused 
Table 3: Active site analysis of DAAO
S. No Type of variant Active site residues
1 DAAO GLN37 GLN38 LYS39 LYS42 SER43 PRO44 LYS45 LEU47 VAL58 PRO59 ARG61 PHE62 ILE75 ALA81 ASP82 TYR86
DAAO: D-amino acid oxidase
Table 4: Molecular docking analysis of antipsychotics with DAAO







Amisulpride −3.97 1.23 −6.35 −6.62 0.26 −1.17 2.39
Amoxapine −4.13 0.94 −7.41 −7.83 0.42 −0.73 3.28
Aripiprazole −4.25 0.76 −6.34 −6.53 0.19 −0.23 2.09
Blonanserin −3.67 2.05 −5.75 −5.9 0.15 −0.01 2.09
Brexpiprazole −5.22 0.14 −7.31 −7.56 0.26 −0.13 2.09
Clocapramine −2.72 10.13 −6.0 −6.55 0.55 −0.95 3.28
Clorotepine −3.46 2.91 −5.55 −5.62 0.07 −047 2.09
Clotiapine −3.04 5.88 −5.13 −5.76 0.63 −0.49 2.09
Clozapine −2.87 7.93 −4.95 −5.55 0.6 −0.66 2.09
Iloperidone 1.0 N/A −4.67 −4.85 0.18 0.09 5.67
DAAO: D-amino acid oxidase, VHBDE: Van der Waals hydrogen bond desolvation energy
Fig. 2: Scheme of Experimental Schedule: Scopolamine‑Induced Amnesia
by scopolamine, a cholinergic antagonist which interferes with 
neurotransmitter transmission within the central nervous 
system [17,18]. The Fig. 2 shows the experimental study, escape latencies 
in Table 2 it indicates a major decrease for clozapine treated group., 
whereas the scopolamine-treated group exhibited a characteristic 
swimming behavior consisting of circling around the pool and longer 
escape latency indicating impairment of their spatial memory. These 
results suggested the cognitive enhancement of clozapine.
CONCLUSION
Clozapine has cognition improvement potential, approving its 
utilization in alleviating toxic effects of scopolamine. Clozapine being 
a DAAO inhibitor is an added benefit for the therapy, and it is a better 
insight for future cognitive studies.
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